Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-19
2011-04-19
Morris, Patricia L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S256000
Reexamination Certificate
active
07928126
ABSTRACT:
A therapeutic drug for cancer containing a substance selected from the group consisting of a novel cyanopyridine derivative, a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate as an active ingredient can be provided.
REFERENCES:
patent: 2005/0256102 (2005-11-01), Claiborne et al.
patent: 2002-95479 (2002-04-01), None
patent: 01/21595 (2001-03-01), None
patent: 02/22601 (2002-03-01), None
patent: 02/066461 (2002-08-01), None
patent: 03/055491 (2003-07-01), None
patent: 2005/013996 (2005-02-01), None
Vippagunta et al., “Crystalline Solid”, Advanced Drug Delivery Reviews 48 (2001) 3-26.
Guillory (in Brittain ed.), “Polymorphism, etc.,” NY: Marcel Dekker, Inc., 1999, 1-2, 183-226.
I. Melnikova et al., “Targeting Protein Kinases”, Nat. Rev. Drug Discovery, vol. 3, pp. 993-994, Dec. 2004.
D. M. Glover et al., “Mutations inauroraPrevent Centrosome Separation Leading to the formation of Monopolar Spindles”, Cell, vol. 81, pp. 95-105, Apr. 7, 1995.
D. Berdnik et al., “Drosophila Aurora-A is Required for Centrosome Maturation and Actin-Dependent Asymmetric Protein Localization During Mitosis”, Current Biology, vol. 12, pp. 640-647, Apr. 16, 2002.
H. Zhou et al., “Tumour Amplified Kinase STK15/BTAK Induces Centrosome Amplification, Aneuploidy and Transformation”, Nature Genetics, vol. 20, pp. 189-193, Oct. 20, 1998.
T. Tanaka et al., “Centrosomal Kinase AIK1 is Overexpressed in Invasive Ductal Carcinoma of the Breast”, Cancer Research, vol. 59, pp. 2041-2044, May 1, 1999.
C. Sakakura et al., “Tumour-Amplified Kinase BTAK is Amplified and Overexpressed in Gastric Cancers with Possible Involvement in Aneuploid Formation”, British Journal of Cancer, vol. 84, No. 6, pp. 824-831, 2001.
S. Sen et al., “Amplification/Overexpression of a Mitotic Kinase Gene in Human Bladder Cancer”, Journal of the National Cancer Institute, vol. 94, No. 17, pp. 1320-1329, Sep. 4, 2002.
D. Li et al., “Overexpression of Oncogenic STK15/BTAK/Aurora A Kinase in Human Pancreatic Cancer”, Clinical Cancer Research, vol. 9, pp. 991-997, Mar. 2003.
Y. M. Jeng et al., “Overexpression and Amplification of Aurora-A in Hepatocellular Carcinoma”, Clinical Cancer Research, vol. 10, pp. 2065-2071, Mar. 15, 2004.
S. Rojanala et al., “The Mitotic Serine Threonine Kinase,Aurora-2is a Potential Target for Drug Development in Human Pancreatic Cancer”, Molecular Cancer Therapeutics, vol. 3, No. 4, pp. 451-457, 2004.
J. R. Bischoff et al., “A Homologue ofDrosophila auroraKinase is Oncogenic and Amplified in Human Colorectal Cancers”, The EMBO Journal, vol. 17, No. 11, pp. 3052-3065, 1998.
E. A. Harrington et al., “VX-680, A Potent and Selective Small-Molecule Inhibitor of the Aurora Kinases, Suppresses Tumor Growth In Vitro”, Nature Medicine, vol. 10, No. 3, pp. 262-267, 2004.
N. Keen et al., “Aurora-Kinase Inhibitors as Anticancer Agents”, Nature Reviews Cancer, vol. 4, No. 12, pp. 927-936, Dec. 2004.
D. Fancelli et al., “Potent and Selective Aurora Inhibitors Identified by the Expansion of a Novel Scaffold for Protein Kinase Inhibition”, J. Med. Chem., vol. 48, pp. 3080-3084, 2005.
R. R. Adams et al., “Human INCENP Colocalizes with the Aurora-B/AIRK2 Kinase on Chromosomes and is Overexpressed in Tumor Cells”, Chromosoma, vol. 110, No. 2, pp. 65-74, 2001.
W. Fischle et al., “Regulation of HP1-Chromatin Binding by Histone H3 Methylation and Phosphorylation”, Nature, vol. 438, pp. 1116-1122, Dec. 2005.
T. Hirota et al., “Histone H3 Serine 10 Phosphorylation by Aurora B Causes HP1 Dissociation from Heterochromatin”, Nature, vol. 438, pp. 1176-1180, Dec. 2005.
J. J. Manfredi et al., “Taxol Binds to Cellular Microtubules”, The Journal of Biology, vol. 94, pp. 688-696, Sep. 1982.
I. Durko et al., “Effects of Two Microtubule-Depolymerizing Drugs, Vincristine and Vinblastine, on Porphyrin Production by Primary Neural Tissue Cultures” Neurochemical Research, vol. 15, No. 11, pp. 1135-1139, 1990.
P. B. Schiff et al., “Promotion of Microtubule Assembly In Vitro by Taxol”, Nature, vol. 277, pp. 665-667, 1979.
Chinese Office Action issued Mar. 10, 2010, in corresponding Chinese Application No. 2006800144518.4, with English translation.
Response to Chinese Office Action (2010), with English translation.
Abe Daisuke
Fujino Yasuhiro
Hayashi Masayuki
Ikegami Hiroshi
Morioka Masahiko
Mitsubishi Tanabe Pharma Corporation
Morris Patricia L
Wenderoth Lind & Ponack, LLP.
LandOfFree
Cyanopyridine derivative and use thereof as medicine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyanopyridine derivative and use thereof as medicine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyanopyridine derivative and use thereof as medicine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2648148